Refined ADC Development Helps Weigh Biomarker-Based Decisions and Treatment Sequencing in Gynecologic Cancers

With multiple antibody-drug conjugates (ADCs) now available for use across ovarian, cervical, and other gynecologic cancers, treatment challenges include matching the right drug to the right patient, navigating biomarker testing nuances, sequencing agents to avoid cross-resistance, and incorporating patient preferences and real-world evidence, rather than relying on head-to-head trials alone.